Myelodysplastic Syndromes Mds clinical trials

Explore recruiting myelodysplastic syndromes mds clinical trials.

Recruiting myelodysplastic syndromes mds studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myelodysplastic Syndromes Mds trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Germany, Italy, Czechia, France, Netherlands, Belgium +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Germany, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

Spain, Belgium, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

ATOMYELO: Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes failing Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Spain, France, Germany, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Italy, Hungary, Spain, Czechia, Germany, Poland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Myelodysplastic Syndromes Mds trials by city

Myelodysplastic Syndromes Mds in Toronto Myelodysplastic Syndromes Mds in Vancouver Myelodysplastic Syndromes Mds in Montreal Myelodysplastic Syndromes Mds in Calgary Myelodysplastic Syndromes Mds in Edmonton Myelodysplastic Syndromes Mds in Ottawa Myelodysplastic Syndromes Mds in Winnipeg Myelodysplastic Syndromes Mds in Quebec City Myelodysplastic Syndromes Mds in Hamilton Myelodysplastic Syndromes Mds in Kitchener Myelodysplastic Syndromes Mds in London Myelodysplastic Syndromes Mds in Halifax Myelodysplastic Syndromes Mds in New York Myelodysplastic Syndromes Mds in Los Angeles Myelodysplastic Syndromes Mds in Chicago Myelodysplastic Syndromes Mds in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease